ATE225341T1 - In 6-position durch thio substituierte paclitaxele - Google Patents

In 6-position durch thio substituierte paclitaxele

Info

Publication number
ATE225341T1
ATE225341T1 AT97954044T AT97954044T ATE225341T1 AT E225341 T1 ATE225341 T1 AT E225341T1 AT 97954044 T AT97954044 T AT 97954044T AT 97954044 T AT97954044 T AT 97954044T AT E225341 T1 ATE225341 T1 AT E225341T1
Authority
AT
Austria
Prior art keywords
paclitaxele
thio
substituted
present
invention concerns
Prior art date
Application number
AT97954044T
Other languages
English (en)
Inventor
Andrew J Staab
John F Kadow
Dolatrai M Vyas
Mark D Wittman
Harold A Mastalerz
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ATE225341T1 publication Critical patent/ATE225341T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D305/00Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/6551Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a four-membered ring
    • C07F9/65512Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a four-membered ring condensed with carbocyclic rings or carbocyclic ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Plant Substances (AREA)
AT97954044T 1996-12-24 1997-12-05 In 6-position durch thio substituierte paclitaxele ATE225341T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3341996P 1996-12-24 1996-12-24
US3635197P 1997-01-23 1997-01-23
PCT/US1997/022152 WO1998028288A1 (en) 1996-12-24 1997-12-05 6-thio-substituted paclitaxels

Publications (1)

Publication Number Publication Date
ATE225341T1 true ATE225341T1 (de) 2002-10-15

Family

ID=26709670

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97954044T ATE225341T1 (de) 1996-12-24 1997-12-05 In 6-position durch thio substituierte paclitaxele

Country Status (11)

Country Link
US (1) US5977386A (de)
EP (1) EP0960107B1 (de)
JP (1) JP2001507029A (de)
AT (1) ATE225341T1 (de)
AU (1) AU722684B2 (de)
CA (1) CA2268774A1 (de)
DE (1) DE69716135T2 (de)
DK (1) DK0960107T3 (de)
ES (1) ES2184149T3 (de)
PT (1) PT960107E (de)
WO (1) WO1998028288A1 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU775373B2 (en) 1999-10-01 2004-07-29 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US6362217B2 (en) 2000-03-17 2002-03-26 Bristol-Myers Squibb Company Taxane anticancer agents
CA2410632A1 (en) 2000-06-22 2001-12-27 David S. Garvey Nitrosated and nitrosylated taxanes, compositions and methods of use
US7351542B2 (en) 2002-05-20 2008-04-01 The Regents Of The University Of California Methods of modulating tubulin deacetylase activity
EP1530465B2 (de) 2002-06-26 2015-12-16 MediGene AG Herstellung einer kationisch liposomalen zubereitung, einen lipophilen wirkstoff enthaltend
CA2525647A1 (en) 2003-05-16 2005-02-24 Intermune, Inc. Synthetic chemokine receptor ligands and methods of use thereof
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
US8691780B2 (en) 2005-02-17 2014-04-08 The Board Of Trustees Of The Leland Stanford Junior University Txr1 and enhanced taxane sensitivity based on the modulation of a pathway mediated thereby
BRPI0709075A2 (pt) 2006-03-20 2011-10-11 Medigene Ag tratamento de cáncer de mama triplo receptor negativo
PL217731B1 (pl) 2006-06-01 2014-08-29 Tomasz Byrski Sposób wykrywania genetycznie uwarunkowanej obniżonej odpowiedzi na chemioterapię cytostatykiem taksanowym, zastosowanie mutacji założycielskiej oraz zestawu do wykrywania takiej odpowiedzi
EP2296645B1 (de) 2008-05-22 2014-11-19 Galera Therapeutics, LLC Antitumorale kombinationstherapie
EP2310507A4 (de) 2008-07-08 2013-03-20 David Gladstone Inst Verfahren und zusammensetzungen zur angiogenesemodulierung
CN102040570B (zh) * 2009-10-14 2014-07-30 江苏先声药物研究有限公司 硫代紫杉烷类衍生物及其制备方法和用途
EP3539563A1 (de) 2012-07-19 2019-09-18 Redwood Bioscience, Inc. Für cd22 spezifischer antikörper und verfahren zur verwendung davon
AU2013341711A1 (en) 2012-11-12 2015-05-21 Redwood Bioscience, Inc. Compounds and methods for producing a conjugate
DK2956175T3 (da) 2013-02-15 2017-11-27 Univ California Kimærisk antigenreceptor og fremgangsmåder til anvendelse deraf
WO2014160185A2 (en) 2013-03-14 2014-10-02 The Board Of Trustees Of The Leland Stanford Junior University Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof
CN115504924A (zh) 2013-11-27 2022-12-23 雷德伍德生物科技股份有限公司 肼基-吡咯并化合物及用于生成缀合物的方法
HUE051255T2 (hu) 2014-02-19 2021-03-01 Aviv Therapeutics Inc Mitokondriális aldehid dehidrogenáz 2 (ALDH2) kötõ policiklusos amidok és alkalmazásuk rák kezelésére
AR099812A1 (es) 2014-03-21 2016-08-17 Abbvie Inc Anticuerpos y conjugados de anticuerpo y fármaco anti-egfr
US10654875B2 (en) 2015-11-12 2020-05-19 The Board Of Trustees Of The Leland Stanford Junior University Cell-penetrating, guanidinium-rich oligophosphotriesters for drug and probe delivery
US20210206826A1 (en) 2015-11-19 2021-07-08 The Regents Of The University Of California Conditionally repressible immune cell receptors and methods of use thereof
TWI760319B (zh) 2015-12-30 2022-04-11 杏國新藥股份有限公司 乳癌治療
EP3231421A1 (de) 2016-04-11 2017-10-18 Greenaltech, S.L. Verwendungen eines carotenoids bei der behandlung oder prävention von durch stress verursachten störungen
JP2019515677A (ja) 2016-04-26 2019-06-13 アール.ピー.シェーラー テクノロジーズ エルエルシー 抗体複合体ならびにそれを作製および使用する方法
CN109640961B (zh) 2016-06-01 2021-11-02 施维雅知识产权英国有限公司 聚亚烷基氧化物-天冬酰胺酶制剂及其制备和使用方法
MX2018015285A (es) 2016-06-08 2019-09-18 Abbvie Inc Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
AU2017279550A1 (en) 2016-06-08 2019-01-03 Abbvie Inc. Anti-B7-H3 antibodies and antibody drug conjugates
WO2017214322A1 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
JP2019524651A (ja) 2016-06-08 2019-09-05 アッヴィ・インコーポレイテッド 抗cd98抗体及び抗体薬物コンジュゲート
US20200147235A1 (en) 2016-06-08 2020-05-14 Abbvie Inc. Anti-cd98 antibodies and antibody drug conjugates
TWI852903B (zh) 2017-01-05 2024-08-21 杏國新藥股份有限公司 胰臟癌治療
JP7280827B2 (ja) 2017-01-18 2023-05-24 エクスマ バイオテック コーポレイション Axlまたはror2に対するキメラ抗原受容体およびその使用方法
EP3388082A1 (de) 2017-04-13 2018-10-17 Galera Labs, LLC Kombinationskrebsimmuntherapie mit makrocyclischem pentaaza-ringkomplex
WO2018218004A1 (en) 2017-05-24 2018-11-29 The Board Of Regents Of The University Of Texas System Linkers for antibody drug conjugates
CN110003142A (zh) * 2018-01-04 2019-07-12 深圳福山生物科技有限公司 一种硒氰化合物及其用途
CA3090129A1 (en) 2018-01-31 2019-08-08 Galera Labs, Llc Combination cancer therapy with pentaaza macrocyclic ring complex and platinum-based anticancer agent
CA3096202A1 (en) 2018-04-06 2019-10-10 The Regents Of The University Of California Methods of treating egfrviii expressing glioblastomas
CA3095757A1 (en) 2018-04-06 2019-10-10 The Regents Of The University Of California Methods of treating glioblastomas
BR112020020930A2 (pt) 2018-04-11 2021-03-02 Ohio State Innovation Foundation composição de liberação de fármaco, método para tratar um distúrbio oftalmológico e kit
CA3105879A1 (en) 2018-07-18 2020-01-23 Manzanita Pharmaceuticals, Inc. Conjugates for delivering an anti-cancer agent to nerve cells, methods of use and methods of making thereof
JP7716623B2 (ja) 2019-04-02 2025-08-01 ウィリアム ロバート アラスーン リビング トラスト デイテッド オーガスト 29, 2016 排出ポンプ-癌抗原マルチ特異性抗体ならびにそれに関する組成物、試薬、キットおよび方法
WO2021155028A1 (en) 2020-01-29 2021-08-05 Kenjockety Biotechnology, Inc. Anti-mdr1 antibodies and uses thereof
WO2021247426A1 (en) 2020-06-04 2021-12-09 Kenjockety Biotechnology, Inc. Anti-abcg2 antibodies and uses thereof
CN116529267A (zh) 2020-06-04 2023-08-01 肯乔克蒂生物技术股份有限公司 Abcg2外排泵-癌症抗原多特异性抗体及其相关组合物、试剂、试剂盒和方法
CA3193588A1 (en) 2020-09-02 2022-03-10 Kenjockety Biotechnology, Inc. Anti-abcc1 antibodies and uses thereof
WO2022103603A1 (en) 2020-11-13 2022-05-19 Kenjockety Biotechnology, Inc. Anti-mrp4 (encoded by abcc4 gene) antibodies and uses thereof
US12187810B2 (en) 2020-11-20 2025-01-07 R.P. Scherer Technologies, Llc Glycoside dual-cleavage linkers for antibody-drug conjugates
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
US20250051471A1 (en) 2021-12-13 2025-02-13 William Robert Arathoon Living Trust Dated August 29, 2016 Anti-Abcb1 Antibodies
WO2023159220A1 (en) 2022-02-18 2023-08-24 Kenjockety Biotechnology, Inc. Anti-cd47 antibodies

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
US4876399A (en) * 1987-11-02 1989-10-24 Research Corporation Technologies, Inc. Taxols, their preparation and intermediates thereof
US4960790A (en) * 1989-03-09 1990-10-02 University Of Kansas Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof
US5714512A (en) * 1991-07-08 1998-02-03 Rhone-Poulenc Rorer, S.A. Compositions containing taxane derivatives
DE69230379T2 (de) * 1991-09-23 2000-05-25 Bristol-Myers Squibb Co., New York 10-disacetoxytaxolderivate
US5272171A (en) * 1992-02-13 1993-12-21 Bristol-Myers Squibb Company Phosphonooxy and carbonate derivatives of taxol
CA2130578A1 (en) * 1992-04-17 1993-10-28 Geewananda P. Gunawardana Taxol derivatives
US5254580A (en) * 1993-01-19 1993-10-19 Bristol-Myers Squibb Company 7,8-cyclopropataxanes
US5294637A (en) * 1992-07-01 1994-03-15 Bristol-Myers Squibb Company Fluoro taxols
FR2697019B1 (fr) * 1992-10-15 1994-11-25 Rhone Poulenc Rorer Sa Nouveaux dérivés du taxane, leur préparation et les compositions pharmaceutiques qui les contiennent.
CA2109861C (en) * 1992-12-04 1999-03-16 Shu-Hui Chen 6,7-modified paclitaxels
CZ292993B6 (cs) * 1992-12-23 2004-01-14 Bristol-Myers Squibb Company Způsob přípravy taxanu nesoucího oxazolinový postranní řetězec a taxan tímto způsobem připravený
MX9308012A (es) * 1992-12-24 1994-08-31 Bristol Myers Squibb Co Eteres fosfonooximetilicos de derivados de taxano, solubles en agua y composiciones farmaceuticas que los incluyen.
US6066747A (en) * 1993-03-05 2000-05-23 Florida State University Process for the preparation of 9-desoxotaxanes
US5703247A (en) * 1993-03-11 1997-12-30 Virginia Tech Intellectual Properties, Inc. 2-Debenzoyl-2-acyl taxol derivatives and methods for making same
ES2205663T3 (es) * 1993-06-11 2004-05-01 PHARMACIA & UPJOHN COMPANY Uso antineoplasico de delta 6,7-taxoles y composiciones farmaceuticas que los contienen.
CA2192373A1 (en) * 1994-06-09 1995-12-14 Hirofumi Terasawa Deacetoxytaxol derivative
DE69504843T2 (de) * 1994-06-28 1999-02-11 Pharmacia & Upjohn Co., Kalamazoo, Mich. 7-äther-taxol ähnliche verbindungen antineoplastische verwendung und diese enthaltende pharmazeutische zusammenstellungen
DE69507702T2 (de) * 1994-07-26 1999-08-26 Indena S.P.A. Semisynthetisch taxal derivate mit antitumor wirkung

Also Published As

Publication number Publication date
AU722684B2 (en) 2000-08-10
DE69716135D1 (en) 2002-11-07
EP0960107A4 (de) 1999-12-01
CA2268774A1 (en) 1998-07-02
DK0960107T3 (da) 2003-02-10
PT960107E (pt) 2003-02-28
JP2001507029A (ja) 2001-05-29
WO1998028288A1 (en) 1998-07-02
DE69716135T2 (de) 2003-06-05
ES2184149T3 (es) 2003-04-01
EP0960107B1 (de) 2002-10-02
EP0960107A1 (de) 1999-12-01
US5977386A (en) 1999-11-02
AU5792298A (en) 1998-07-17

Similar Documents

Publication Publication Date Title
ATE225341T1 (de) In 6-position durch thio substituierte paclitaxele
FI943749A0 (fi) Taksaanijohdannaisten fosfono-oksimetyylieetterit
FI954979A7 (fi) Kemoherkistävinä aineina käytettävät 10,11-metanodibentsosuberaanijohdannaiset
FI952248L (fi) Kasvainvastaisia koostumuksia, jotka sisältävät taksaanijohdannaisia
DK0971717T3 (da) Cytotoksiske aminosukker- og relaterede sukkerderivater af indolopyrrolocarbazoler
ES2181744T3 (es) Hidratos de paclitaxel cristalinos.
IL160051A0 (en) Ecteinascidin derivatives and pharmaceutical compositions containing the same
ATE231872T1 (de) Thiazolopyrimidinderivate
MX9601994A (es) Profarmacos de derivados de paclitaxel.
ATE388960T1 (de) Glykopeptidderivate mit carboxysacchariden
SE9802937D0 (sv) Novel compounds
CA2152771A1 (en) 7-o-ethers of taxane derivatives
TR200001102T2 (tr) İkameli tetrahidropirimidinen türevleri, üretimleri ve kullanımları.
DZ1576A1 (fr) Compostions therapeutiques à base de dérives de 1,2-dithiole-3-thione.
ATE250340T1 (de) 7-methylthiooxomethyl- und 7- methylthiodioxomethyl-paclitaxele
EP1263749A4 (de) Taxan-derivate für die behandlung von krebs
DE69107742D1 (de) Substituierte 3,7,9-Trioxa-1-aza-2,8-diphosphaspiro[4.5]dekane und stabilisierte Zusammensetzungen.
NO20021429L (no) 1,4-dioksacykloalkan-2-oner og 1,4-dioksacykloalken-2-oner
FI950101A7 (fi) 4-oksa-1-atsabisyklo 3,2,0 -7heptanoni-johdannaiset kasvainten vastaisina aineina
DE69202762D1 (de) 6,9-Bis(amino substituierte) Benzo(G)Phthalazin-5,10-Dionen als Antikrebs-mittel.
GR1001394B (el) Παράγωγα 4-[4-[4-(4-υδροξυφαινυλ)-1-πιπεραζινυλ] φαινυλ]-5-με?υλ3Η-1,2,4-τριαζολ-3-όνης.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0960107

Country of ref document: EP

REN Ceased due to non-payment of the annual fee